Evidence Hub

Development and validation of an RP-hplc method for the estimation of sildenafil, fluoxetine, and lovastatin

Indu Melkani, Bimlesh Kumar, Shashi, Narendra Kumar Pandey

Asian Journal of Pharmaceutical and Clinical Research, 2025

Abstract

Objective: Neuropathic pain (NP) arises from trauma to the somatosensory nervous system and can be managed using selective serotonin reuptake inhibitors, such as fluoxetine (FLX) and phosphodiesterase inhibitors, such as sildenafil (SD), and cholesterol-lowering agents such as lovastatin (LOVA). The present study aimed to develop and validate an analytical method for the simultaneous estimation of these drugs (SD, FLX, and LOVA [SFL]) using reverse-phase high-performance liquid chromatography (RP-HPLC). Methods: An RP-HPLC method was developed and validated for the quantification of SFL. Chromatographic separation was achieved using a C-18 reverse-phase ODS column with a mobile phase consisting of acetonitrile and 0.2 M ammonium acetate buffer (55:45) in gradient elution mode. The flow rate was maintained at 1 mL/min, and detection was carried out at 228 nm. The method was validated following the ICH Q2 (R2) guidelines, assessing parameters such as linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ). Results: The developed method exhibited linearity within the concentration range of 20–100 μg/mL, with a regression coefficient (r2) of 0.9992. Retention times for FLX, SD, and LOVA were recorded at 6.481, 4.238, and 19.778 min, respectively. Recovery studies demonstrated an accuracy range of 94.61–110.44%, with a relative standard deviation of 0.06–2.00%, confirming the precision of the method. The LOD values for FLX, SD, and LOVA were…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free